search.noResults

search.searching

saml.title
dataCollection.invalidEmail
note.createNoteMessage

search.noResults

search.searching

orderForm.title

orderForm.productCode
orderForm.description
orderForm.quantity
orderForm.itemPrice
orderForm.price
orderForm.totalPrice
orderForm.deliveryDetails.billingAddress
orderForm.deliveryDetails.deliveryAddress
orderForm.noItems
Company insight


Build confidence through testing


WuXi AppTec Medical Device Testing supports hundreds of thousands of devices with the strategies and testing needed to gain market access, avoid costly delays and support changing requirements throughout a product’s life cycle.


T


oday’s complex global regulatory environment creates a challenging situation for many medical device manufacturers who are developing a strategy that meets the changing testing requirements. Partners with a pulse on evolving expectations can help proactively plan for new and upcoming standards. With the recent changes to ISO 10993 chapters, new approaches to preclinical safety testing should be considered. WuXi AppTec Medical Device Testing has partnered with thousands of companies in its path towards approvals with regulatory bodies worldwide. Its experts are leading global standards committees and frequently communicate with regulators, and track and trend feedback, resulting in an extensive understanding of the latest and future requirements. From advising testing plans, and supporting responses and justifications requested during the review process, it has plenty to share regarding ISO 10993.


A device’s full story


Before the release of ISO 10993-1:2018, manufacturers were used to conducting a more standardised set of tests based on


the nature and duration of device contact. With the 2018 revisions, the evaluation of a device’s biological safety experienced significant change. Physical and chemical device information was now the foundation for identifying device-specific risks and manufacturers needed to develop biological test strategies based on those risks. Over time, the requirements for conducting chemistry testing have become more rigorous. As a result, regulators supported refining acceptable testing plans to include chemical characterisation. These analytically selective and sensitive methods began to prove their value as the industry shifted from a checklist approach to a more strategic biological safety testing method.


Establish consistency


The publication of ISO 10993-18:2020 created a ‘common language’ between two integral parts of the evaluation process and helped establish manufacturer expectations from laboratory partners. It also introduced the analytical evaluation threshold (AET), which converts a dose-based threshold used by toxicologists to a concentration-based threshold used by chemists.


The AET requires a partnership between the chemist and toxicologist who will perform the risk assessment. The industry continuously establishes more consistent and thorough evaluation procedures that better recognise each device’s chemical risks. Regulators are gradually implementing enhanced material identification expectations, so manufacturers must pay close attention and frequently assess their compliance with the latest requirements. “ISO 10993-18 revisions have been a major learning curve for any laboratory. Laboratories who are underprepared or less engaged in the regulatory landscape can cause significant and unexpected delays for their clients,” says Sandi Schaible, senior director of analytical chemistry and regulatory toxicology at WuXi AppTec Medical Device Testing. Building out the capabilities to support such identification requires investing in time, technology and internal support. More than ever, chemists and toxicologists are working closer together, highlighting the value of integrated laboratories with notable regulatory involvement.


Change on the horizon


As the latest chemical characterisation methods reveal more materials, a growing amount of data challenges toxicologists to determine the steps for evaluating the remaining risks. Upcoming changes to ISO 10993-17 will help usher in a new era of streamlined toxicological risk assessments. Managing a range of products during this transition can be an arduous process, but it will benefit devices and patients in the long run. Companies heightening their strategies for gathering preclinical safety and regulatory compliance information will face many guidance updates, but they don’t have to do it alone. ●


WuXi AppTec Medical Device Testing can help medical device manufacturers understand the ever-evolving regulatory landscape.


34 https://medicaldevice.wuxiapptec.com Medical Device Developments / www.nsmedicaldevices.com


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92  |  Page 93  |  Page 94  |  Page 95  |  Page 96  |  Page 97  |  Page 98  |  Page 99  |  Page 100  |  Page 101  |  Page 102  |  Page 103  |  Page 104  |  Page 105  |  Page 106  |  Page 107  |  Page 108  |  Page 109  |  Page 110  |  Page 111  |  Page 112  |  Page 113  |  Page 114  |  Page 115  |  Page 116  |  Page 117  |  Page 118  |  Page 119  |  Page 120  |  Page 121  |  Page 122  |  Page 123  |  Page 124  |  Page 125  |  Page 126  |  Page 127  |  Page 128  |  Page 129  |  Page 130  |  Page 131  |  Page 132  |  Page 133